We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

39 hedge funds and large institutions have $3.66M invested in Matinas BioPharma in 2018 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 7 increasing their positions, 14 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

3.08% less ownership

Funds ownership: 12.05% → 8.97% (-3.1%)

13% less funds holding

Funds holding: 45 → 39 (-6)

32% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 19

50% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 14

58% less capital invested

Capital invested by funds: $8.74M → $3.66M (-$5.08M)

Holders
39
Holders Change
-6
Holders Change %
-13.33%
% of All Funds
0.89%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
7
Reduced
14
Closed
19
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$272K
2
ECM
Element Capital Management
New York
+$227K
3
PP
Paloma Partners
Connecticut
+$173K
4
IA
IFP Advisors
Florida
+$173K
5
BCM
BlueCrest Capital Management
Jersey
+$143K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$1.39M
2
State Street
State Street
Massachusetts
-$471K
3
AWMG
Alliance Wealth Management Group
New Jersey
-$307K
4
Northern Trust
Northern Trust
Illinois
-$290K
5
BCM
Bridgeway Capital Management
Texas
-$145K

MTNB Hedge Fund Activity: Q2 2018 in Review

39 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q2 2018, worth a combined $3.66M — down 58% from $8.74M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of MTNB and 13 opened new positions — a net loss of 6 holders — while 14 trimmed existing stakes and 7 added.

The largest buyer was Goldman Sachs, adding an estimated $272K. The largest seller was BlackRock, cutting an estimated $1.39M.

  • 39 institutional investors held Matinas BioPharma (MTNB) as of Q2 2018, down from 45 in Q1 2018.
  • Funds reported $3.66M of Matinas BioPharma stock for Q2 2018, down 58% quarter-over-quarter.
  • 13 funds opened new Matinas BioPharma positions in Q2 2018 and 19 closed out, a net change of -6 holders.
  • The largest Matinas BioPharma buyer in Q2 2018 was Goldman Sachs, an estimated $272K added.
  • The largest Matinas BioPharma seller in Q2 2018 was BlackRock, an estimated $1.39M sold.

Based on aggregated 13F filings for Q2 2018.